COMPARE · Data as of August 21, 2026
HALO vs PTCT
Verdict: Side-by-side breakdown using the Bull Rankings model. HALO scored 79.5, PTCT scored 24.7 — HALO leads.
Compare another set
HALO
Halozyme Therapeutics, Inc.
79.5
$108.17 · $12.3B
fundamentals as of
Score gap
54.8
HALO leads
PTCT
PTC Therapeutics, Inc.
24.7
$69.82 · $5.8B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthHALO+41.2%
- Highest qualityHALO96 / 100
- Largest discount to fair valueHALO-38%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
HALO
stronger →← stronger
PTCT
96
Qualityreturns · margins · balance sheet
39
97
Growthrevenue & earnings expansion
15
54
Valuevaluation vs sector peers
26
HALO is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
HALO
PTCT
$806mC+
FCF
-$40mF
+41.2%A
Rev
-42.8%F
31.7xB
P/E
—
1.47B
PEG
—
—
P/S
5.8xB
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
HALO
PTCT
38% below
Price vs fair valuelower is cheaper
—
~1%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
+29%
1-yr DCF upside
—
+63%
5-yr DCF upside
—
+129%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
HALO
Why this score
- Buying back stock
- Durable high returns
PTCT
Why this score
- Diluting shareholders
The companies
HALOHalozyme Therapeutics, Inc.
Why now
Biotechnology · market cap $12.3b. Trading near 52-week high of $108.49 — momentum setup, limited technical margin of safety. Revenue growing +41% — in hypergrowth territory. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $99.56 (implying -8% upside).
Moat
Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 32x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
PTCTPTC Therapeutics, Inc.
Why now
Biotechnology · market cap $5.8b. Down 23% from 52-week high of $90.87 — deep drawdown territory. Revenue -43% — in contraction; any catalyst that reverses this triggers re-rating. 14 sell-side analysts rate this a Buy with a mean 1-yr target of $99.29 (implying +42% upside).
Moat
ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$40m) — capital raises or debt issuance likely required; dilution / leverage risk. Revenue contracting -43% — the operational turn is not yet visible in the top line. Currently unprofitable (margin -3.8%) — path to GAAP profitability is the core thesis risk.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where HALO and PTCT diverge
On the headline score the gap is 54.8 points in favor of HALO. The widest single difference is Growth, where HALO leads by 82.3 points.
- GrowthHALO 97.0 · PTCT 14.7HALO +82.3
- QualityHALO 95.7 · PTCT 39.2HALO +56.5
- ValueHALO 54.1 · PTCT 26.0HALO +28.1
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.